Researcher Profiles

Return to member profile

Howard L. Kaufman, MD, FACS

Publications since 2011

Kaufman, H. L. Kim, D. W. Kim-Schulze, S. Deraffele, G. Joagoda, M. C. Broucek, J. Zloza, A. Results of a Randomized Phase I Gene Therapy Clinical Trial of Non-oncolytic Fowlpox Viruses Encoding T cell Co-stimulatory Molecules. Hum Gene Ther, 25:452-460, . (PMID: 24484178, PMCID: PMC4027985)

Kaufman, H. L. Melanoma as a model for precision medicine in oncology. Lancet Oncol, 15:251-253, . (PMID: 24508105)

Zloza, A. Kim, D. W. Kim-Schulze, S. Jagoda, M. C. Monsurro, V. Marincola, F. M. Kaufman, H. L. Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses. J Immunother Cancer, 2:1, . (PMID: 24829758, PMCID: PMC4019911)

Kim, D. W. Zloza, A. Broucek, J. Schenkel, J. M. Ruby, C. Samaha, G. Kaufman, H. L. Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells. J Transl Med, 12:113, . (PMID: 24885155, PMCID: PMC4062649)

Kaufman, H. L. Ruby, C. E. Hughes, T. Slingluff, C. L. Jr Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer, 2:11, . (PMID: 24971166, PMCID: PMC4072479)

Wong, M. K. Kaufman, H. L. Daniels, G. A. McDermott, D. F. Aung, S. Lowder, J. N. Morse, M. A. Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes. J Immunother Cancer, 2:20, . (PMID: 25031835, PMCID: PMC4100489)